ACIU AC Immune SA

5.38
+0.24  (+5%)
Previous Close 5.14
Open 5.18
Price To Book 1.3
Market Cap 363,485,352
Shares 67,562,333
Volume 108,004
Short Ratio
Av. Daily Volume 100,275

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
Crenezumab - CREAD 2
Alzheimer’s disease
Phase 2 data due 3Q 2020.
RG6100 (Anti-Tau RO7105705)
Alzheimer’s disease
Phase 1/2 interim data released July 2019.
ACI-24 (anti-Abeta vaccine)
Alzheimer's disease-like characteristics in individuals with Down syndrome
Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
Crenezumab - CREAD 1
Alzheimer’s disease
Phase 2 trial initiation announced August 20, 2018.
ACI-24
Alzheimer’s disease
Phase 2 trial initiation announced February 20, 2019.
MTAU9937A
Alzheimer’s disease
Phase 2 trial planned for 1H 2019.
ACI-35
Alzheimer’s disease
Phase 1 trial initiation announced July 17, 2019.
ACI-3024
Alzheimer’s disease
Phase 1b/2 trial initiation announced August 1, 2019.
ACI-35.030
Alzheimer’s Disease

Latest News

  1. AC Immune Reports Q2 2019 Financial Results, Business and Clinical Update
  2. AC Immune Announces Research Collaboration with University of Pennsylvania Focusing on Pathogenic Protein TDP-43 in Neurodegenerative Diseases
  3. Analysts Estimate AC Immune (ACIU) to Report a Decline in Earnings: What to Look Out for
  4. AC Immune Initiates Phase I Study for Alzheimer's Disease
  5. AC Immune Initiates Phase 1 Study of ACI-3024 Small Molecule Tau Morphomer™, an Investigational Treatment for Alzheimer’s Disease
  6. AC Immune Hosts KOL Event and Reports Initial Interim Clinical Data for ACI-24 Vaccine to Treat Alzheimer’s Disease-like Symptoms in Subjects with Down Syndrome
  7. Introducing AC Immune (NASDAQ:ACIU), The Stock That Slid 66% In The Last Year
  8. Here’s What Hedge Funds Think About AC Immune SA (ACIU)
  9. AC Immune Announces Election of New Chairman of the Board at Annual General Meeting
  10. AC Immune to Host Key Opinion Leader Meeting on Treating Alzheimer’s in Down Syndrome
  11. AC Immune Reports Initiation of a Phase 2 Substudy to Increase Understanding of Disease Progression in Familial Alzheimer’s Disease
  12. AC Immune (ACIU) Lags Q1 Earnings and Revenue Estimates
  13. AC Immune: 1Q Earnings Snapshot
  14. AC Immune Reports Q1 2019 Financial Results and Business Update
  15. AC Immune (ACIU) to Report Q1 Results: Wall Street Expects Earnings Growth
  16. What Percentage Of AC Immune SA (NASDAQ:ACIU) Shares Do Insiders Own?
  17. Alector (ALEC) Initiates Phase I Alzheimer's Study on AL003
  18. AC Immune to Present at the H.C. Wainwright Global Life Sciences Conference
  19. AC Immune Presents New Data on Alpha-Synuclein PET Tracer at AD/PD™ Conference